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STUDY PROTOCOL Open Access
Combined extracorporeal shock wave
lithotripsy and endoscopic treatment for
pain in chronic pancreatitis (SCHOKE trial):
study protocol for a randomized, sham-
controlled trial
Søren S. Olesen1*, Asbjørn M. Drewes1, Rajesh Gaud2, Manu Tandan2, Sundeep Lakhtakia2, Mohan Ramchandani2,
G. V. Rao3, D. Nageshwar Reddy2 and Rupjyoti Talukdar2,4
Abstract
Background: Pain is the primary symptom of chronic pancreatitis (CP) and remains a considerable therapeutic
challenge. In patients with obstruction of the pancreatic duct, including stones and strictures, endoscopic treatment
with or without preceding extracorporeal shock wave lithotripsy (ESWL) has been used for pancreatic duct
decompression. The rationale for these procedures is based on the assumption that obstruction of the pancreatic
duct leads to ductal hypertension and pain. However, clinical pain symptoms correlate poorly with pancreatic duct
morphology, and the evidence for pancreatic duct decompression as an effective treatment for pain is based on
case series and comparison between different procedures. No randomized, prospective, sham-controlled trials are
currently available. The SCHOKE (Extracorporeal Shock Wave Lithotripsy and Endotherapy for Pain in Chronic
Pancreatitis) trial is a randomized, sham-controlled trial designed to determine if pancreatic duct decompression is
an effective treatment for pain in patients with CP.
Methods: The SCHOKE trial is a randomized, single-blind, parallel-group, sham-controlled trial designed to evaluate
the effect of combined ESWL and endoscopic treatment for pain in patients with CP. In total, 106 adult patients
with painful CP and pancreatic duct obstruction will be randomized to combined ESWL and subsequent
endoscopic treatment or corresponding sham procedures. The primary outcome is pain relief during the 3-month
postrandomization period as documented in a pain diary. Secondary outcomes include quality of life and functional
scores, patient global impression of change, change in use of analgesics, frequency of hospitalization, and
complications. Standard follow-up is at 3 and 6 months after randomization. In an experimental substudy,
quantitative sensory testing obtained before and after intervention will be used to obtain information on central
pain processing and to develop models for prediction of treatment outcome.
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Discussion: The SCHOKE trial investigates if pancreatic duct decompression, obtained by combined ESWL and
endoscopic treatment, is effective for pain treatment in patients with CP.
Trial registration: ClinicalTrials.gov, NCT03966781. Registered on May 25, 2019.
Protocol date and version identifier: March 1, 2020; version 3.0.
Sponsor: Rupjyoti Talukdar, Department of Medical Gastroenterology, Asian Institute of Gastroenterology,
Hyderabad, Telangana, India.
Introduction
Pain is the primary symptom of chronic pancreatitis (CP)
and remains a considerable therapeutic challenge [1]. In
patients with pathological changes of the pancreatic duct,
including stones and strictures, endoscopic treatment with
or without preceding extracorporeal shock wave litho-
tripsy (ESWL) and surgery has been used with varying
success to treat pain [2–4]. The rationale for such invasive
procedures is based on the hypothesis that obstruction of
the pancreatic duct leads to ductal hypertension and pain
[5, 6]. However, clinical pain symptoms correlate poorly
with pancreatic ductal morphology, as assessed by cross-
sectional imaging [7, 8], and the response to endoscopic
or surgical treatment is unpredictable, with long-term re-
sponse rates ranging from 30% to 60% [3, 9, 10]. Also, the
evidence for these treatments is based on case series and
comparison between different procedures; no randomized,
prospective, sham-controlled trials have evaluated the ef-
fectiveness of invasive treatments for pain in CP [9–11].
Additionally, a marked placebo effect has been observed
in most trials of painful CP, and this, together with the
natural history of disease, needs consideration when treat-
ment effects are evaluated [12–14]. Therefore, the evi-
dence for invasive treatments for pain in CP can be
questioned [14].
Recent meta-analyses have documented that nonspecific
effects of invasive procedures are generally large, particularly
in the field of pain-related conditions and for endoscopy-
based therapies [15, 16]. For example, endoscopic retrograde
cholangiopancreatography (ERCP) with sphincterotomy (bil-
iary or pancreatic sphincterotomy or both) has for many
years been considered the state-of-the-art treatment for pa-
tients with abdominal pain due to suspected sphincter of
Oddi dysfunction. However, a high-quality randomized con-
trolled trial (RCT) showed that patients who had no sphinc-
terotomy at ERCP, and who were blinded to their treatment,
reported as much pain relief as those who underwent
sphincterotomy [17, 18]. These findings challenge conven-
tional wisdom and underscore the necessity for appropriately
conducted RCTs to include a sham procedure when the ef-
fectiveness of invasive procedures is evaluated [14].
Albeit endoscopic treatment or surgery is widely used
for pain in CP, these treatments are only effective in a sub-
set of patients [4, 9, 19, 20]. An improved understanding
of the mechanisms underlying pain in CP suggests that
the pain etiology in most patients is multifactorial, and, in
addition to the proposed mechanisms for pain (ductal ob-
struction/hypertension), a large body of evidence supports
a “neuropathic pain phenotype” with abnormal processing
in the peripheral and central neural pathways [6, 21, 22].
Invasive procedures will not be effective in neuropathic
pain and can even be considered harmful [14]. This likely
explains the variable response to endoscopic and surgical
treatments and underlines an unmet need for biomarkers
to identify responders to the different treatment modalities.
Quantitative sensory testing (QST) can be used to in-
vestigate the state of the pain system. The technique is
based on the rationale that different neural pathways
and networks can be explored using standardized stimu-
lation with simultaneous recording of the evoked pain
response by psychophysical and/or objective methods
[23]. Due to spinal convergence between visceral affer-
ents from the pancreas and somatic afferents from the
T10 skin dermatome, somatic QST can reliably be used
to assess if the pain system is locally sensitized by noci-
ceptive input from the pancreas (segmental sensitization)
[24, 25]. However, in many patients with chronic pain,
the pain system has become dysfunctional and has
undergone widespread sensitization, which is evident as
abnormal responses (hyperalgesia) to stimuli applied in
areas remote from the pancreas [26]. Taken together,
QST profiling based on testing in several dermatomes,
together with specific test paradigms (temporal summa-
tion and assessment of descending inhibition), can be
used to determine whether patients have abnormal cen-
tral pain processing or evidence of segmental or wide-
spread sensitization [27–29].
Methods
The study protocol is reported in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines (Additional file 1).
Study hypothesis and aim
The hypothesis of the study is that pancreatic duct de-
compression following ESWL and endoscopic treatment
induces short-term (3 months) and midterm (6months)
pain relief in patients with CP compared with a sham
Olesen et al. Trials          (2020) 21:338 Page 2 of 9
procedure. In addition, we hypothesize that QST can be
used to predict the outcome of treatment. Hence, pa-
tients with evidence of widespread sensitization of cen-
tral pain pathways are hypothesized to have a worse
outcome after ESWL and endoscopic treatment than pa-
tients with no evidence of widespread sensitization.
Study design and setting
We are conducting a randomized, single-blind, single-
center, parallel-group, sham-controlled, prospective trial
designed to evaluate the effect of combined ESWL and
endoscopic treatment for pain in adult patients with CP.
The study will be conducted at the tertiary care aca-
demic Asian Institute of Gastroenterology in Gachibowli,
Hyderabad, India.
Inclusion criteria
 A diagnosis of chronic calcific pancreatitis diagnosed
using the Mayo Clinic diagnostic criteria [30]. Both
diabetic and nondiabetic patients will be allowed to
enter the study.
 Age ≥ 18 years.
 Chronic abdominal pain characteristic for CP with a
pain intensity > 3 on a 0–10 visual analogue scale
(VAS) and meeting the criteria for chronic pain
(pain ≥ 3 days per week for ≥ 3 months).
 Obstruction of the pancreatic duct due to
intraductal stones with dilation of the duct proximal
to the obstruction, as determined by magnetic
resonance cholangiopancreatography (MRCP) or
abdominal computed tomography (CT).
 The patients must be able to read and understand
the provided informed consent form.
 Patients must personally sign and date the informed
consent document, indicating that he/she has been
informed of all pertinent aspects of the trial.
 Patients should be willing to comply with the
scheduled visits, clinical and experimental
assessment plans, and other trial procedures.
Exclusion criteria
 Patients with any clinically significant laboratory
abnormalities that, in the opinion of the investigator,
may increase the risk associated with trial
participation or may interfere with the
interpretation of the trial results.
 Previous history of pancreatic surgery, ESWL, or
ERCP.
 Patients with a pancreatic stricture on cross-
sectional imaging prior to study enrollment.
 Active alcohol or illicit drug dependency.
 Patients with evidence or history of medical or
surgical disease of importance for this study as
judged by the investigator.
 Patients must not have painful conditions other than
CP that make them unable to distinguish the pain
associated with CP from chronic pain of other
origin.
 Presence of pancreatic head mass, multiple
strictures, large ascites, and/or large fluid collections.
Interventions
Patients will be randomly allocated to either combined
ESWL and endoscopic treatment or sham treatment.
Combined ESWL and endoscopic treatment
Patients enrolled in the active treatment group will be
subjected to ESWL followed by ERCP. In India, patients
with CP typically present with large pancreatic stones
that tend to be dense and spiculated. In order to ensure
complete stone clearance, ESWL and ERCP are therefore
performed together and in agreement with clinical prac-
tice in most centers [10, 31].
ESWL will be conducted with the patient under epi-
dural anesthesia. For epidural anesthesia, bupivacaine
will be used to block the T6–T12 thoracic spinal seg-
ments. The patient’s eyes will be lightly covered during
the procedure. Once epidural anesthesia is achieved, the
patient will be given a light sedation, and ESWL will be
performed using a third-generation Dornier dual focus
lithotripsy system (Dornier Delta 3; Dornier MedTech
GmbH, Weßling, Germany), providing a maximum of
5000 shocks at the rate of 90 shocks per minute. If
complete stone clearance is not achieved during the first
ESWL session, a second session will be scheduled the
following day.
After lithotripsy, stone fragments will be removed dur-
ing an ERCP procedure. An endoscopic pancreatic
sphincterotomy will be performed, and complete stone
removal will be attempted with registration of pancreatic
duct clearance. If cannulation fails after a maximum of
five attempts, the patient will be subjected to precut
sphincterotomy. In case a pancreatic duct stricture is
identified during the ERCP procedure that was not de-
tected by MRCP prior to enrollment, the stricture is di-
lated and followed by pancreatic stent insertion. A
pancreatic duct stent will also be inserted in case of in-
complete stone removal during the ERCP procedure.
Patients undergoing pancreatic duct stenting will be re-
ferred for a new ERCP procedure after 6months for stent
exchange or removal (after completion of all study assess-
ments). When complete runoff of contrast material is ob-
served after removal of the stent and an extraction balloon
can be passed through the pancreatic duct, endoscopic
treatment is considered completed, and further stenting
Olesen et al. Trials          (2020) 21:338 Page 3 of 9
will be stopped. Persistent strictures will be treated by re-
peated endoscopic dilations and sequential insertion of
new stents in agreement with the European Society of
Gastrointestinal Endoscopy guidelines [32].
Sham treatment
In the sham/control group, patients will be given a tran-
sient superficial pinprick sensation to give the feeling of
epidural anesthesia prior to sham ESWL. Subsequently,
the lithotripsy machine will be switched on, without es-
tablishing any form of contact with the patient’s body.
The patient’s eyes will be lightly covered during the en-
tire procedure. Following sham ESWL, patients will be
subjected to sham ERCP with duodenal intubation of
the endoscope and examination of the papillary area, but
no pancreatic ductal intervention will be performed.
Concomitant medication
Patients will be instructed not to change their regular
pain treatment during the trial period. Regular pain
treatment will be recorded twice: at the screening visit
and at the last visit. Rescue pain medication, taken on an
“as needed basis,” is allowed throughout the trial period,
and its use will be documented and quantified in the
pain diary. Patients with exocrine pancreatic insuffi-
ciency will remain on enzyme replacement therapy dur-
ing the trial period and follow-up.
Outcomes
The study consists of a clinical part and an experimental
part. The clinical part of the study aims to investigate
the pain-relieving effects of combined ESWL and endo-
scopic treatment in patients with painful CP in compari-
son with sham treatment. The experimental part of the
study aims to evaluate if QST profiles obtained prior to
ESWL and endoscopic intervention can be used for pre-
diction of treatment outcome.
Primary clinical endpoint
The primary clinical endpoint is pain relief. Average and
maximal daily clinical pain intensity scores will be re-
corded in a patient pain diary based on a 0–10 VAS,
with registration of the baseline pain intensity scores
done in the week prior to intervention and weekly re-
cordings continued for a 3-month period after interven-
tion. Mean values of pain scores will be calculated over
1 week to adjust for day-to-day variability in pain inten-
sity. The difference in pain scores between patients re-
ceiving active treatment (ESWL and ERCP) and sham
treatment are compared, with the primary comparison
of average pain scores 3 months after intervention.
Weekly telephone interviews from a study coordinator
will be undertaken to facilitate accurate registration and
compliance pain score.
Secondary clinical endpoints
 Difference between groups in pain scores after 6
months.
 The ratio of responders versus nonresponders
defined by a decrease in the average clinical pain
score (VAS) of 30% after 3 and 6 months compared
with baseline.
 Difference between groups in number of pain-free
days after 3 and 6 months.
 Change in analgesic consumption (if used) after 3
and 6 months compared with baseline.
 Difference between groups in total number of
hospitalizations during the study period.
 Difference between groups in total duration of
hospital stays during the study period.
 Difference in total loss of working days due to CP
between groups during the study period.
 Difference between groups in cumulative cost
attributed to CP-related treatment and disability
(loss of working days) during the study period.
 Difference between groups in quality of life using
the European Organization for Research and
Treatment of Cancer Quality of Life questionnaire
after 3 and 6 months [15].
 Difference between groups in pain and physical
functioning composite scores of the modified Brief
Pain Inventory–short form after 3 and 6months [16].
 Difference between groups in depression and anxiety
scores of the Hospital Anxiety and Depression Scale
after 3 and 6 months [33].
 Patient global impression of change after 3 and 6
months [18].
 Assessment of complications resulting from
interventions during the study period.
Experimental endpoints
The following experimental pain measures will be
employed prior to intervention as well as 24–48 h and 3
months after intervention to characterize changes in
pain processing induced by the assigned procedures:
 Muscle pressure stimulation (pancreatic viscerotome
[T10 ventral and dorsal] and control areas [C5, L1
and L4])
 Bone pressure stimulation (tibia bone)
 Temporal summation to repetitive pinprick
stimulations of the pancreatic area (T10) and
control area [dominant forearm])
 Conditioned pain modulation (CPM)
Sample size determination
The study is powered to detect a minimal difference be-
tween groups of 30% in the average clinical pain score 3
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months after intervention [34]. On the basis of an as-
sumed SD of 45%, we determine that a study with 48 pa-
tients per group is needed to provide power of 90% (to
allow secondary endpoints) with the use of a two-sided
significance level of 0.05 [35]. To allow a 10% dropout
rate, the sample size is set at 106 patients.
Randomization, blinding, and treatment allocation
Randomization is performed using an automatic assign-
ment system that conceals allocation. Block randomization
is employed with randomization of six patients per block to
equal proportions for sham procedures or combined ESWL
and endotherapy. No stratification of randomization based
on demographic or clinical variables will be applied. The al-
location sequence will be generated by a biostatistician who
will not be involved in the administration of treatment or
recording of data. Randomization of patients into the two
groups will be done by a physician who will not have access
to the clinical data of the patients.
The patients will be blinded to the treatment received.
The patients in the sham procedure will be provided a
superficial needle prick with a sterile needle to mimic
epidural anesthesia. Then the ESWL instrument will be
started so that the patients get an auditory perception
that the treatment is being provided. The patient’s eyes
will be covered, and if the patient wishes, he or she will
be given light sedation. The operator cannot be blinded,
owing to the nature of the study. However, the principal
investigator and the statistician will be blinded to the
treatment arms.
In case of an emergency that necessitates knowledge
of the procedure allocation, the individual procedure as-
signment for each patient will be available. The codes
will be available at the study center in sealed envelopes
that are stored in a locked and secured area accessible
only to those individuals authorized by the investigator.
This procedure allows unblinding of individual subjects,
without revealing codes of the entire study. The investi-
gator will be able to determine which procedure a pa-
tient was given by opening the sealed envelope with the
corresponding randomization number. The investigator
must state the reason why the code was broken on the
envelope and must date and sign it. At the end of the
study, all sealed and unsealed envelopes must be
accounted for.
Outcome measures
At baseline, the following assessment parameters will be
registered (Fig. 1): age and sex; etiology and duration of
CP; past history of acute pancreatitis; current alcohol and
smoking status; the presence of CP complications, includ-
ing exocrine pancreatic insufficiency and diabetes mellitus;
cross-sectional imaging results; current medications, in-
cluding analgesics; and past history of endoscopic and
surgical treatment. Data will be collected using a paper
case report form and later entered into an electronic data-
base with double data entry check.
The follow-up duration is 6months from randomization
with scheduled visits after 3months (primary study
period) and 6months (follow-up). The questionnaires and
pain diary used for collection of clinical endpoints are de-
scribed in the previous sections on primary and secondary
clinical endpoints. In addition, QST profiles will be re-
corded prior to intervention as well as 24–48 h after and
3months after intervention. A schedule for the study as-
sessment parameters is provided in Fig. 1.
Quantitative sensory testing
Repetitive pinprick stimulation (temporal summation)
Recording of temporal summation to repetitive pinprick
stimulations in the pancreatic and control areas (midline
volar site of dominant forearm) will be employed using a
256-nm von Frey hair (Pin-Prick Stimulatoren; MRC
Systems GmbH, Heidelberg, Germany). Pain ratings
using a 0–10 numerical rating scale will be obtained
after a single application and after the last application in
a series of ten repetitive stimuli with an interstimulus
interval of 1 s. For accurate timing of the stimuli, the
procedure is guided by an auditory signal using a metro-
nome. The difference between the last and the first pain
ratings of the ten stimuli will be recorded as the tem-
poral summation score.
Muscle pressure stimulation
The pressure pain detection threshold (PDT) and pain
tolerance threshold (PTT) will be determined for the fol-
lowing skin dermatomes: C5 (clavicula), T10 ventral
(upper epigastric area; pancreatic viscerotome), T10 back
(pancreatic viscerotome), L1 (anterior superior iliac
crest), and L4 (the quadriceps 15 cm above the patella).
All lateralized pressure stimulations will be applied on
the patient’s dominant side. An electronic pressure alg-
ometer (AlgoMed; Medoc Ltd., Ramat Yishai, Israel)
with a probe surface area of 1 cm2 will be used for the
pressure stimulations. Pressure will be increased in two
separate sessions at a rate of 30 kPa/s until the PDT or
PTT is reached. The assessment parameter is the pres-
sure at the predefined sensory threshold measured in
kilopascals.
Cold pressor test
The dominant hand is immersed in an ice-chilled water
bucket (2.0 °C ± 0.3 °C). The patient will be told to re-
move the hand from the water after 2 min of immersion
or sooner if the pain is intolerable. The patients rate the
pain intensity for every 10 s during the cold pressor test
using a 0–10 VAS. If the patient withdraws their hand
sooner than 2 min because of intolerable pain, the VAS
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will be considered to be 10 for the remaining period of
time, and the time for withdrawal of the hand will be
noted.
Conditioned pain modulation
CPM is a clinically measurable form of descending pain
modulation that can be induced experimentally by a
conditioning stimulus (the cold pressor test) and quanti-
fied by applying a “test pain” (pressure stimulation on
the nondominant quadriceps musculature 4 cm above
the patella) before and after the conditioning stimulus
[36]. The difference in pressure stimulus intensity (PTT)
before and after the cold pressor test provides a quanti-
tative index of the CPM capacity in the individual pa-
tient. The techniques used for pressure stimulation and
cold pressor test described above will be combined to
measure CPM.
Pancreatic imaging
Cross-sectional imaging (CT and MRCP) will be used to
evaluate the pancreatic morphology prior to study
enrollment based on usual clinical practice. All patients
enrolled in the study will have their imaging parameters
reviewed and described by an expert radiologist (Dr.
Ashirwad).
Statistical analysis
The primary analysis of clinical endpoints will be by
intention to treat, meaning that all randomized patients
are included in their initially assigned study arm, regard-
less of adherence to the study protocol. Experimental
endpoints will be evaluated by per-protocol analysis,
meaning that only patients completing the experimental
setup will be included. A repeated measures linear mixed
effects model will be used for the primary analysis and
will include terms for treatment group, assessment time
point (week), and the interaction of treatment with as-
sessment time point. Summary statistics of pain scores
will be provided for the individual time points, and the
difference in pain scores between groups after 3 months
is considered the primary efficacy parameter. Subgroup
and covariate analyses will be performed if applicable
STUDY PERIOD
Enrolment Allocation Primary study period Follow-up
TIMEPOINT Week -1 0 Week 1 Month 3 Month 6
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
ESWL & ERCP X
Sham treatment X
ASSESSMENTS:
Baseline variables a
X
Primary outcome b
X
Secondary outcomes c
X X X
Experimental outcomes d
X X X
Fig. 1 Schedule of enrollment, interventions, and assessments. aBaseline variables: age; sex; etiology and duration of chronic pancreatitis (CP);
history of acute pancreatitis; current alcohol and smoking status; complications of CP, including exocrine pancreatic insuficiency (EPI) and
diabetes mellitus; cross-sectional imaging results; medications, including analgesics; and past history of endoscopic and/or surgical treatment.
bPrimary outcome: Pain scores documented in a weekly pain diary based on a 0–10 visual analogue scale. cSecondary outcomes: Pain scores after
6 months, > 30% pain relief, number of pain-free days, analgesic consumption, frequency of hospitalizations, quality of life (European Organization
for Research and Treatment of Cancer Quality of Life questionnaire), pain and physical functioning composite scores (modified Brief Pain
Inventory–short form), anxiety and depression scores, patient global impression of change, and complications. dQuantitative sensory testing
assessment parameters. ERCP Endoscopic retrograde cholangiopancreatography, ESWL Extracorporeal shock wave lithotripsy
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and in case differences in patient subgroups deemed
clinically relevant are evident. Subsequent analyses di-
rected at the secondary, experimental, and safety end-
points are analyzed using appropriate statistics,
including mixed effect models, Fisher’s exact tests, and
Student’s t tests or Wilcoxon rank-sum tests as appro-
priate. The predictive value of the QST profiles will be
analyzed using logistic regression models.
We plan to conduct an interim analysis after approxi-
mately one-third of patients (n = 40) have been random-
ized and have completed 6 months of follow-up, using a
two-sided significance test with the O’Brien–Fleming
spending function and a type I error rate of 5%. An inde-
pendent statistician, blinded to the treatment allocation,
will perform the interim analysis. The statistician will re-
port to an independent data and safety monitoring board
(DSMB). The DSMB will have unblinded access to all data
and will decide on the continuation of the trial and report
to the internal review board of the Asian Institute of
Gastroenterology. If there is a highly significant difference
in improvement in pain in the treatment arm, then all
subsequent patients will be subjected to this. The trial will
not be stopped in case of futility, unless the DSMB advises
otherwise during the course of safety monitoring.
Monitoring and safety
Prior to trial initiation, a DSMB comprising a neurologist,
an anesthesiologist, and a statistician (all from outside the
study center) will be constituted. The DSMB will conduct
periodic monitoring to ensure that the protocol and good
clinical practice standards are followed. The monitors may
review source documents to confirm that data recorded
on case report forms are accurate. The investigator and
institution will allow the DSMB and appropriate regula-
tory authorities direct access to source documents to per-
form this verification. The trial site may be subject to
review by the institutional review boards, and/or to quality
assurance audits performed by the DSMB, and/or to in-
spection by appropriate regulatory authorities. The DSMB
will also conclude on the planned interim analysis.
There is no anticipated harm or compensation for trial
participation. The ESWL and ERCP procedures on pa-
tients with CP are currently used in daily clinical prac-
tice, and participation in the study is not expected to be
associated with an increased risk of adverse events com-
pared with standard clinical care. Following ESWL, we
have observed mild erythema at the site of stimulation.
There has been a very infrequent incidence of acute pan-
creatitis after the procedure. Because ERCP is associated
with an increased risk of post-procedure acute pancrea-
titis, means to decrease this risk (rectal indomethacin
and preprocedural intravenous fluids) will be used in
high-risk patients.
Discussion
Pain is the primary symptom of CP and is associated
with poor health-related outcomes, including reduced
life quality, disability, and increased health resource use
[37–39]. Pain treatment is unsatisfactory in a large pro-
portion of patients and generally based on low-quality
evidence in particular for invasive treatments (endoscopy
and surgery) [14]. The SCHOKE (Extracorporeal Shock
Wave Lithotripsy and Endotherapy for Pain in Chronic
Pancreatitis) trial is a randomized, sham-controlled trial
designed to determine if pancreatic duct decompression
is an effective approach for obtaining pain relief in pa-
tients with CP. According to current guidelines, invasive
procedures are recommended for pain treatment in the
context of CP, and some practitioners even advocate for
surgical treatment in the early phase of CP [32, 40, 41].
However, neither surgery nor endoscopic therapy has
been thoroughly evaluated in sham-controlled trials [14].
The present study will, for the first time, provide sham-
controlled evidence for the effectiveness of pancreatic
duct decompression as a remedy to relieve pain in CP.
The mechanisms responsible for pain in patients
with CP are multifactorial, and thus it is to be ex-
pected that no treatment can effectively relieve pain
in all patients [42]. Identification of biomarkers that
link pain mechanisms with specific treatment modal-
ities is therefore an unmet need in the field, but there
are currently few personalized approaches to pain
treatment in CP [29]. For example, the presence, se-
verity, and temporal nature of pain correlate poorly
with imaging findings, and, as such, imaging can only
be used to identify cases in which an invasive treat-
ment is technically feasible, but it cannot be used to
determine if patients will benefit from the planned
treatment [7, 8, 43]. A QST protocol designed for
characterization of pancreatic pain has previously
shown effectiveness for the prediction of analgesic
outcome in patients with CP and may serve as a use-
ful biomarker for endoscopic treatment efficacy as
well [24]. The SCHOKE trial therefore includes a
QST testing paradigm specifically developed to assess
and characterize pain in CP [29].
In conclusion, the SCHOKE trial is a randomized,
sham-controlled trial that investigates whether pancre-
atic duct decompression is effective for obtaining pain
relief in patients with painful CP.
Trial status
Ethical approval has been obtained, and the trial was
registered with ClinicalTrials.gov on May 25, 2019
(NCT03966781). The first patient was randomized by
January 4, 2020, and recruitment is expected to be com-
pleted July 1, 2021.
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